Trial Profile
A Multicenter, Open-Label Phase III Study to Evaluate the Safety and Efficacy of ISU302 (Imiglucerase for Injection) in Patients With Type 1 Gaucher Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Imiglucerase (Primary)
- Indications Anaemia; Gaucher's disease type I
- Focus Registrational; Therapeutic Use
- Sponsors ISU Abxis
- 18 May 2016 New trial record